Operating Segments (Tables)

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and six months ended June 30, 2019 and 2018 (in thousands).

Segment Reporting for the Quarter Ended June 30, 2019
	Treatment			Services			Medical			Segments Total			Corporate(1)			Consolidated Total
Revenue from external customers	$	10,094		$	7,041			—		$	17,135		$	—		$	17,135
Intercompany revenues		7			42			—			49			—			—
Gross profit		2,627			644			—			3,271			—			3,271
Research and development		136			—			80			216			7			223
Interest income		—			—			—			—			107			107
Interest expense		(30	)		(4	)		—			(34	)		(73	)		(107	)
Interest expense-financing fees		—			—			—			—			(60	)		(60	)
Depreciation and amortization		233			79			—			312			5			317
Segment income (loss) before income taxes		1,611			137			(80	)		1,668			(1,289	)		379
Income tax expense		6			—			—			6			—			6
Segment income (loss)		1,605			137			(80	)		1,662			(1,289	)		373
Expenditures for segment assets		73			15			—			88			—			88

Segment Reporting for the Quarter Ended June 30, 2018
	Treatment			Services		Medical			Segments Total			Corporate(1)			Consolidated Total
Revenue from external customers	$	9,146		$	4,014		—		$	13,160		$	—		$	13,160
Intercompany revenues		77			26		—			103			—			—
Gross profit		1,523			520		—			2,043			—			2,043
Research and development		115			—		71			186			33			219
Interest income		—			—		—			—			81			81
Interest expense		(8	)		—		—			(8	)		(54	)		(62	)
Interest expense-financing fees		—			—		—			—			(9	)		(9	)
Depreciation and amortization		227			123		—			350			9			359
Segment income (loss) before income taxes		2,028	(2)		116		(71	)		2,073			(1,266	)		807
Income tax expense		14			—		—			14			5			19
Segment income (loss)		2,014			116		(71	)		2,059			(1,271	)		788
Expenditures for segment assets		271			35		—			306			—			306

Segment Reporting for the Six Months Ended June 30, 2019
	Treatment			Services			Medical			Segments Total			Corporate(1)			Consolidated Total
Revenue from external customers	$	19,999		$	8,844			—		$	28,843		$	—		$	28,843
Intercompany revenues		9			63			—			72			—			—
Gross profit		5,584			188			—			5,772			—			5,772
Research and development		283			—			154			437			13			450
Interest income		—			—			—			—			188			188
Interest expense		(47	)		(13	)		—			(60	)		(134	)		(194	)
Interest expense-financing fees		—			—			—			—			(70	)		(70	)
Depreciation and amortization		470			157			—			627			14			641
Segment income (loss) before income taxes		3,487			(875	)		(154	)		2,458			(2,590	)		(132	)
Income tax expense		45			—			—			45			—			45
Segment income (loss)		3,442			(875	)		(154	)		2,413			(2,590	)		(177	)
Expenditures for segment assets		294			18			—			312			—			312

Segment Reporting for the Six Months Ended June 30, 2018
	Treatment			Services			Medical			Segments Total			Corporate(1)			Consolidated Total
Revenue from external customers	$	18,105		$	7,712			—		$	25,817		$	—		$	25,817
Intercompany revenues		289			39			—			328			—			—
Gross profit		4,303			1,060			—			5,363			—			5,363
Research and development		228			—			172			400			51			451
Interest income		—			—			—			—			130			130
Interest expense		(8	)		(1	)		—			(9	)		(106	)		(115	)
Interest expense-financing fees		—			—			—			—			(18	)		(18	)
Depreciation and amortization		467			246			—			713			18			731
Segment income (loss) before income taxes		3,772	(2)		31			(172	)		3,631			(2,521	)		1,110
Income tax expense		65			—			—			65			5			70
Segment income (loss)		3,707			31			(172	)		3,566			(2,526	)		1,040
Expenditures for segment assets		106			10			—			116			—			116

⁽¹⁾ Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾ Amounts included a net gain of $1,596,000 recorded resulting from the exchange offer of the Series B Preferred Stock of our M&EC subsidiary which was consummated on May 30, 2018.